PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma

In this single-center,open-label, phase I study, the safety and efficacy of PIN in combination with programmed cell death protein antibody (anti-PD1) therapeutic regimen will be evaluated in patients with refractory primary advanced hepatocellular carcinoma(HCC) . A total of 25 to 30 patients are planned to be enrolled and receive PIN plus anti-PD1 combined treatment. It aims to: 1).assess the safety and antitumor effects of the above combined treatment regimen. 2).detect the dynamic changes and molecular characteristics of PIN-induced CD8+ T cells with special phenotype in peripheral blood (P

Trial Details

NCT ID
NCT07018518
Phase
PHASE1
Sponsor
Chinese PLA General Hospital
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • PIN +anti-PD1
Locations (sample)
  • Beijing, Biotherapeutic Department of Chinsese PLA Gereral Hospital, China|39.9075,116.39723

Key Eligibility Criteria

  • Age 18-75 (inclusive).
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2 and Estimated life expectancy of more than 3 months.
  • Histopathological /cytological or diagnosed clinically confirmed locally advanced or metastatic HCC having undergone treatments recommended by the …
  • At least one measurable lesion at baseline according to investigators Response Evaluation Criteria in Solid Tumours 1.1 (RECIST 1.1).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →